Scripps Research Logo

News Release

Scripps Florida Team Awarded $1.2 Million to Develop Drug Candidates for Rheumatoid Arthritis and Neurodegenerative Disorders

JUPITER, FL, January 25, 2013 –Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

Derek R. Duckett, associate scientific director in TSRI’s Translational Research Institute, and Peter S. Hodder, senior director of lead identification at the Translational Research Institute, will act as co-principal investigators for the three-year grant.

The project will focus on an enzyme known as ASK1, which is part of a larger family of mitogen-activated protein kinases (MAP kinases) that help control how cells respond to stress and is involved in mediating cell survival and programmed cell death (apoptosis). Genetic target validation studies have demonstrated that loss of this kinase shows remarkable efficacy in animal models of various diseases.

“While ASK1 is a highly druggable target, no tool compounds are currently available to probe its biology,” Duckett pointed out. “This award will help us remedy the situation.”

The new grant will allow the Scripps Florida scientists to perform a high-throughput screening campaign of the TSRI compound collection at their state-of-the-art screening facility. “Our team approach will identify the best lead molecules that will help define the roles that ASK1 plays in normal physiological processes as well as in disease states,” Duckett said. “Such leads will also serve as good starting material for chemistry optimization efforts for future therapeutics.”

“A very exciting prospect of this research effort is that Scripps’s drug discovery compound collection will be assayed for novel inhibitors of ASK1 activity,” said Hodder. “Past screening efforts with this collection yielded the antecedents of clinically relevant compounds, and the research plan we have in place bodes well for a similar outcome from this effort.”

 The number of the new National Institutes of Health grant is 1R01GM103957-01.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

# # #

For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8136
press@scripps.edu